Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Joint Metastasis Research Society-AACR Conference on Metastasis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 51, 6199-6201, November 15, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chitambar, C. R.
Right arrow Articles by O'Brien, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chitambar, C. R.
Right arrow Articles by O'Brien, W. J.

Inhibition of Ribonucleotide Reductase by Gallium in Murine Leukemic L1210 Cells1

Christopher R. Chitambar2, Jana Narasimhan, Julie Guy, Daniel S. Sem3 and William J. O'Brien

Division of Cancer and Blood Diseases, Department of Medicine [C. R. C., J. N.], and Departments of Ophthalmology and Microbiology [J. G., W. J. O.], Medical College of Wisconsin, Milwaukee, Wisconsin 53226

Our previous studies of the mechanism of cell growth inhibition by gallium have suggested that the block in cellular iron uptake induced by transferrin-gallium results in an inhibition of the iron-dependent M2 subunit of ribonucleotide reductase. However, it is not known whether the inhibitory effect of gallium on ribonucleotide reductase is solely the result of limiting iron availability for enzyme activity or whether a direct effect of intracellular gallium on the enzyme is also involved. In the present study, utilizing a cell-free assay, we show that gallium nitrate directly inhibits CDP and ADP reductase activity. Inhibition of DNA synthesis by gallium nitrate thus appears to be due to a combination of a block in iron availability to ribonucleotide reductase and a direct inhibition of the enzyme by gallium.

1 This work was supported by USPHS Grants R01 CA41740 (C. R. C.) and NEI P30-EY01931 (W. J. O.).

2 To whom requests for reprints should be addressed, at Division of Cancer and Blood Diseases, Medical College of Wisconsin, 8700 W. Wisconsin Ave., Milwaukee, WI 53226.

3 Present address: McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, WI.

Received 9/10/91. Accepted 9/27/91.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
C. R. Chitambar, D. P. Purpi, J. Woodliff, M. Yang, and J. P. Wereley
Development of Gallium Compounds for Treatment of Lymphoma: Gallium Maltolate, a Novel Hydroxypyrone Gallium Compound, Induces Apoptosis and Circumvents Lymphoma Cell Resistance to Gallium Nitrate
J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1228 - 1236.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Yang, S. H. Kroft, and C. R. Chitambar
Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate
Mol. Cancer Ther., February 1, 2007; 6(2): 633 - 643.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. R. Chitambar, J. P. Wereley, and S. Matsuyama
Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition.
Mol. Cancer Ther., November 1, 2006; 5(11): 2834 - 2843.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
Z. M. Qian, H. Li, H. Sun, and K. Ho
Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway
Pharmacol. Rev., December 1, 2002; 54(4): 561 - 587.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
S. C. Dixon, K. B. Knopf, and W. D. Figg
The Control of Prostate-Specific Antigen Expression and Gene Regulation by Pharmacological Agents
Pharmacol. Rev., March 1, 2001; 53(1): 73 - 92.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
L. R. Bernstein
Mechanisms of Therapeutic Activity for Gallium
Pharmacol. Rev., December 1, 1998; 50(4): 665 - 682.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. R. Chitambar and J. P. Wereley
Transferrin Receptor-Dependent and -Independent Iron Transport in Gallium-Resistant Human Lymphoid Leukemic Cells
Blood, June 15, 1998; 91(12): 4686 - 4693.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. R. Chitambar and J. P. Wereley
Resistance to the Antitumor Agent Gallium Nitrate in Human Leukemic Cells Is Associated with Decreased Gallium/Iron Uptake, Increased Activity of Iron Regulatory Protein-1, and Decreased Ferritin Production
J. Biol. Chem., May 2, 1997; 272(18): 12151 - 12157.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1991 by the American Association for Cancer Research.